OBJECTIVES: The objective of this double-blind randomised, placebo-controlled study was to examine the efficacy and safety intramuscular vitamin B12 (Tricortin 1000) in the treatment of low back pain in patients with mechanical or irritative lumbago. METHODS:60 patients aged between 18 and 65 years with lumbago or sciatic neuritis of mechanical origin without need for surgical procedures were enrolled. Patients had to present with a proven medical history for back pain (lasting from 6 months to 5 years) and a pain intensity [as evaluated with a Visual Analogic Scale (VAS)] equal or greater than 60 mm. Efficacy primary end-point was evaluated by means of a visual analogic scale (VAS) and a Disability Questionnaire (DQ). Consumption of paracetamol during the study period was the secondary efficacy end-point. RESULTS: Both treatment groups experienced a sharp decrease in pain and disability. However, comparison between groups at the end of the treatment period showed a statistically significant difference in favour of the active treatment both for VAS and DQ (p < 0.0001 and p < 0.0002, respectively). Consumption of paracetamol proved significantly higher in the placebo group than in the active treatment (p < 0.0001). CONCLUSIONS: The efficacy and safety of parenteral Vitamin B12 in alleviating low back pain and related disability and in decreasing the consumption of paracetamol was confirmed in patients with no signs of nutritional deficiency.
RCT Entities:
OBJECTIVES: The objective of this double-blind randomised, placebo-controlled study was to examine the efficacy and safety intramuscular vitamin B12 (Tricortin 1000) in the treatment of low back pain in patients with mechanical or irritative lumbago. METHODS: 60 patients aged between 18 and 65 years with lumbago or sciatic neuritis of mechanical origin without need for surgical procedures were enrolled. Patients had to present with a proven medical history for back pain (lasting from 6 months to 5 years) and a pain intensity [as evaluated with a Visual Analogic Scale (VAS)] equal or greater than 60 mm. Efficacy primary end-point was evaluated by means of a visual analogic scale (VAS) and a Disability Questionnaire (DQ). Consumption of paracetamol during the study period was the secondary efficacy end-point. RESULTS: Both treatment groups experienced a sharp decrease in pain and disability. However, comparison between groups at the end of the treatment period showed a statistically significant difference in favour of the active treatment both for VAS and DQ (p < 0.0001 and p < 0.0002, respectively). Consumption of paracetamol proved significantly higher in the placebo group than in the active treatment (p < 0.0001). CONCLUSIONS: The efficacy and safety of parenteral Vitamin B12 in alleviating low back pain and related disability and in decreasing the consumption of paracetamol was confirmed in patients with no signs of nutritional deficiency.
Authors: J Vidal-Alaball; C C Butler; R Cannings-John; A Goringe; K Hood; A McCaddon; I McDowell; A Papaioannou Journal: Cochrane Database Syst Rev Date: 2005-07-20
Authors: Marco Antonio Naslausky Mibielli; Carlos Pereira Nunes; Henrique Goldberg; Luiz Buchman; Lisa Oliveira; Spyros G E Mezitis; Fernanda Wajnzstajn; Renato Kaufman; Rafael Nigri; Natasha Cytrynbaum; Karin Soares Cunha; Alessandra Santos; Stephanie Wrobel Goldberg; Natália Carvalho Platenik; Helio Rzetelna; Daniel Bertoluci Futuro; Adenilson de Souza Da Fonseca; Mauro Geller Journal: J Pain Res Date: 2020-10-13 Impact factor: 3.133
Authors: Nicholas Henschke; Ton Kuijpers; Sidney M Rubinstein; Marienke van Middelkoop; Raymond Ostelo; Arianne Verhagen; Bart W Koes; Maurits W van Tulder Journal: Eur Spine J Date: 2010-04-29 Impact factor: 3.134
Authors: Bruce H R Wolffenbuttel; Hanneke J C M Wouters; M Rebecca Heiner-Fokkema; Melanie M van der Klauw Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2019-05-27